| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ibrutinib | CTRPv2 | pan-cancer | AAC | 0.016 | 0.7 |
| mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |
| mRNA | Imatinib | FIMM | pan-cancer | AAC | 0.074 | 0.7 |
| mRNA | 968 | CTRPv2 | pan-cancer | AAC | -0.024 | 0.7 |
| mRNA | pandacostat | CTRPv2 | pan-cancer | AAC | 0.014 | 0.7 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.013 | 0.7 |
| mRNA | C6-ceramide | CTRPv2 | pan-cancer | AAC | 0.013 | 0.7 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
| mRNA | AZD7762 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.7 |
| mRNA | Bexarotene | FIMM | pan-cancer | AAC | -0.059 | 0.7 |